Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL Meeting Abstract
| Authors: | Zelenetz, A. D.; Jurczak, W.; Ribrag, V.; Linton, K.; Collins, G. P.; López-Jiménez, J.; Reddy, N.; Mengarelli, A.; Phillips, T. J.; Musuraca, G.; Sheehy, O.; Li, J.; Xu, W.; Azoulay, M. M.; Ghalie, R.; Zinzani, P. L. |
| Abstract Title: | Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680301972 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.7511 |
| Notes: | Meeting Abstract: 7511 -- Meeting also held virtually -- Source: Wos |
